Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection

Ruoke Wang; Yang Han; Rui Zhang; Jiayi Zhu; Xuanyu Nan; Yaping Liu; Ziqing Yang; Bini Zhou; Jinfang Yu; Zichun Lin; Jinqian Li; Peng Chen; Yangjunqi Wang; Yujie Li; Dongsheng Liu; Xuanling Shi; Xinquan Wang; Qi Zhang; Yuhe R. Yang; Taisheng Li; Linqi Zhang

doi:10.1016/j.immuni.2023.10.007

Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection

Ruoke Wang, Yang Han, Rui Zhang, Jiayi Zhu, Xuanyu Nan, Yaping Liu, Ziqing Yang, Bini Zhou, Jinfang Yu, Zichun Lin, Jinqian Li, Peng Chen, Yangjunqi Wang, Yujie Li, Dongsheng Liu, Xuanling Shi, Xinquan Wang, Qi Zhang, Yuhe R. Yang^*, Taisheng Li^*Linqi Zhang^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

The 2003 severe acute respiratory syndrome coronavirus (SARS-CoV-1) causes more severe disease than SARS-CoV-2, which is responsible for COVID-19. However, our understanding of antibody response to SARS-CoV-1 infection remains incomplete. Herein, we studied the antibody responses in 25 SARS-CoV-1 convalescent patients. Plasma neutralization was higher and lasted longer in SARS-CoV-1 patients than in severe SARS-CoV-2 patients. Among 77 monoclonal antibodies (mAbs) isolated, 60 targeted the receptor-binding domain (RBD) and formed 7 groups (RBD-1 to RBD-7) based on their distinct binding and structural profiles. Notably, RBD-7 antibodies bound to a unique RBD region interfaced with the N-terminal domain of the neighboring protomer (NTD proximal) and were more prevalent in SARS-CoV-1 patients. Broadly neutralizing antibodies for SARS-CoV-1, SARS-CoV-2, and bat and pangolin coronaviruses were also identified. These results provide further insights into the antibody response to SARS-CoV-1 and inform the design of more effective strategies against diverse human and animal coronaviruses.

Original language	English
Pages (from-to)	2635-2649.e6
Journal	Immunity
Volume	56
Issue number	11
DOIs	https://doi.org/10.1016/j.immuni.2023.10.007
Publication status	Published - 14 Nov 2023
Externally published	Yes

Access to Document

10.1016/j.immuni.2023.10.007

Cite this

Wang, R., Han, Y., Zhang, R., Zhu, J., Nan, X., Liu, Y., Yang, Z., Zhou, B., Yu, J., Lin, Z., Li, J., Chen, P., Wang, Y., Li, Y., Liu, D., Shi, X., Wang, X., Zhang, Q., Yang, Y. R., ... Zhang, L. (2023). Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection. Immunity, 56(11), 2635-2649.e6. https://doi.org/10.1016/j.immuni.2023.10.007

@article{c272ee2f090d4e46b5944a0b396eabf7,

title = "Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection",

abstract = "The 2003 severe acute respiratory syndrome coronavirus (SARS-CoV-1) causes more severe disease than SARS-CoV-2, which is responsible for COVID-19. However, our understanding of antibody response to SARS-CoV-1 infection remains incomplete. Herein, we studied the antibody responses in 25 SARS-CoV-1 convalescent patients. Plasma neutralization was higher and lasted longer in SARS-CoV-1 patients than in severe SARS-CoV-2 patients. Among 77 monoclonal antibodies (mAbs) isolated, 60 targeted the receptor-binding domain (RBD) and formed 7 groups (RBD-1 to RBD-7) based on their distinct binding and structural profiles. Notably, RBD-7 antibodies bound to a unique RBD region interfaced with the N-terminal domain of the neighboring protomer (NTD proximal) and were more prevalent in SARS-CoV-1 patients. Broadly neutralizing antibodies for SARS-CoV-1, SARS-CoV-2, and bat and pangolin coronaviruses were also identified. These results provide further insights into the antibody response to SARS-CoV-1 and inform the design of more effective strategies against diverse human and animal coronaviruses.",

keywords = "antibody grouping, antibody response, cross reactivity, cryo-EM structure, epitope mapping, monoclonal antibody, neutralizing antibodies, RBD antibody, SARS-CoV-1, SARS-CoV-2",

author = "Ruoke Wang and Yang Han and Rui Zhang and Jiayi Zhu and Xuanyu Nan and Yaping Liu and Ziqing Yang and Bini Zhou and Jinfang Yu and Zichun Lin and Jinqian Li and Peng Chen and Yangjunqi Wang and Yujie Li and Dongsheng Liu and Xuanling Shi and Xinquan Wang and Qi Zhang and Yang, {Yuhe R.} and Taisheng Li and Linqi Zhang",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = nov,

day = "14",

doi = "10.1016/j.immuni.2023.10.007",

language = "English",

volume = "56",

pages = "2635--2649.e6",

journal = "Immunity",

issn = "1074-7613",

publisher = "Cell Press",

number = "11",

}

Wang, R, Han, Y, Zhang, R, Zhu, J, Nan, X, Liu, Y, Yang, Z, Zhou, B, Yu, J, Lin, Z, Li, J, Chen, P, Wang, Y, Li, Y, Liu, D, Shi, X, Wang, X, Zhang, Q, Yang, YR, Li, T & Zhang, L 2023, 'Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection', Immunity, vol. 56, no. 11, pp. 2635-2649.e6. https://doi.org/10.1016/j.immuni.2023.10.007

TY - JOUR

T1 - Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection

AU - Wang, Ruoke

AU - Han, Yang

AU - Zhang, Rui

AU - Zhu, Jiayi

AU - Nan, Xuanyu

AU - Liu, Yaping

AU - Yang, Ziqing

AU - Zhou, Bini

AU - Yu, Jinfang

AU - Lin, Zichun

AU - Li, Jinqian

AU - Chen, Peng

AU - Wang, Yangjunqi

AU - Li, Yujie

AU - Liu, Dongsheng

AU - Shi, Xuanling

AU - Wang, Xinquan

AU - Zhang, Qi

AU - Yang, Yuhe R.

AU - Li, Taisheng

AU - Zhang, Linqi

PY - 2023/11/14

Y1 - 2023/11/14

N2 - The 2003 severe acute respiratory syndrome coronavirus (SARS-CoV-1) causes more severe disease than SARS-CoV-2, which is responsible for COVID-19. However, our understanding of antibody response to SARS-CoV-1 infection remains incomplete. Herein, we studied the antibody responses in 25 SARS-CoV-1 convalescent patients. Plasma neutralization was higher and lasted longer in SARS-CoV-1 patients than in severe SARS-CoV-2 patients. Among 77 monoclonal antibodies (mAbs) isolated, 60 targeted the receptor-binding domain (RBD) and formed 7 groups (RBD-1 to RBD-7) based on their distinct binding and structural profiles. Notably, RBD-7 antibodies bound to a unique RBD region interfaced with the N-terminal domain of the neighboring protomer (NTD proximal) and were more prevalent in SARS-CoV-1 patients. Broadly neutralizing antibodies for SARS-CoV-1, SARS-CoV-2, and bat and pangolin coronaviruses were also identified. These results provide further insights into the antibody response to SARS-CoV-1 and inform the design of more effective strategies against diverse human and animal coronaviruses.

AB - The 2003 severe acute respiratory syndrome coronavirus (SARS-CoV-1) causes more severe disease than SARS-CoV-2, which is responsible for COVID-19. However, our understanding of antibody response to SARS-CoV-1 infection remains incomplete. Herein, we studied the antibody responses in 25 SARS-CoV-1 convalescent patients. Plasma neutralization was higher and lasted longer in SARS-CoV-1 patients than in severe SARS-CoV-2 patients. Among 77 monoclonal antibodies (mAbs) isolated, 60 targeted the receptor-binding domain (RBD) and formed 7 groups (RBD-1 to RBD-7) based on their distinct binding and structural profiles. Notably, RBD-7 antibodies bound to a unique RBD region interfaced with the N-terminal domain of the neighboring protomer (NTD proximal) and were more prevalent in SARS-CoV-1 patients. Broadly neutralizing antibodies for SARS-CoV-1, SARS-CoV-2, and bat and pangolin coronaviruses were also identified. These results provide further insights into the antibody response to SARS-CoV-1 and inform the design of more effective strategies against diverse human and animal coronaviruses.

KW - antibody grouping

KW - antibody response

KW - cross reactivity

KW - cryo-EM structure

KW - epitope mapping

KW - monoclonal antibody

KW - neutralizing antibodies

KW - RBD antibody

KW - SARS-CoV-1

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85176269266&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2023.10.007

DO - 10.1016/j.immuni.2023.10.007

M3 - Article

C2 - 37924813

AN - SCOPUS:85176269266

SN - 1074-7613

VL - 56

SP - 2635-2649.e6

JO - Immunity

JF - Immunity

IS - 11

ER -

Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection

Abstract

Access to Document

Other files and links

Fingerprint

Cite this